{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Synaptogenix Schedules Business Update Conference Call - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"c6YWLBPs8t\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/synaptogenix-schedules-business-update-conference-call\/\">Synaptogenix Schedules Business Update Conference Call<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/synaptogenix-schedules-business-update-conference-call\/embed\/#?secret=c6YWLBPs8t\" width=\"600\" height=\"338\" title=\"&#8220;Synaptogenix Schedules Business Update Conference Call&#8221; &#8212; Market Newsdesk\" data-secret=\"c6YWLBPs8t\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ &#8212;\u00a0Synaptogenix, Inc.\u00a0(OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced the successful spin-off of substantially all of the legacy assets and liabilities of Neurotrope, Inc. last week. The Company plans to hold an audio conference call for investors on Tuesday, December 15, 2020 at 4:15 p.m. ET to provide a general business update. \u00a0 To participate in the briefing session, please click on the link below to register. Event Link: https:\/\/www.webcaster4.com\/Webcast\/Page\/2599\/39136 Participant Dial In: Toll Free: 877-407-9205; International: 201-689-8054 About Synaptogenix, Inc. Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer&#8217;s &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY23404&amp;sd=2020-12-15"}